Article Data

  • Views 474
  • Dowloads 138

Original Research

Open Access

Possible relevance of tumor-related genes mutation to malignant transformation of endometriosis

  • X. Ma1,*,
  • Y. Hui2
  • L. Lin1
  • Y. Wu1
  • X. Zhang1
  • X. Qin1

1Department of Gynecology and Obstetrics, Liaocheng People's Hospital and Clinical Teaching Hospital of Taishan Medical College, Liaocheng, Shandong, China

2Department of Neurosurgery, Liaocheng People's Hospital and Clinical Teaching Hospital of Taishan Medical College, Liaocheng, Shandong, China

DOI: 10.12892/ejgo2734.2016 Vol.37,Issue 1,February 2016 pp.89-94

Published: 10 February 2016

*Corresponding Author(s): X. Ma E-mail: XiaopingMa20@yeah.net

Abstract

Objective: Despite studies have suggested that endometriosis has malignant potential, the molecular mechanism underlying the malignant transformation of endometriosis is poorly understood so far. Endometriosis-associated ovarian cancer (EAOC) or ovarian cancer arising from endometriosis (OCEM) may provide an ideal model for genetic studies.To investigate the genetic alterations during transformation of ovarian endometriosis into cancer, the authors analysed mutations of tumour-related genes (PTEN and p53) in EAOC cases (n = 23, group 1), including 19 cases which were detected co-existence of endometriosis and cancer and four cases which fulfilled the histological criteria in malignant transformation of endometriosis (OCEMs), and in atypical hyperplasia ovarian endometriosis (aEMs) (n = 10, group 2), as well as in solitary ovarian endometriosis (EMs) (n = 20, group 3), simultaneously, to study the correlation of the two genes in the development and progression of the ovarian endometriosis malignancy. Materials and Methods: Each paraffin block was sliced into serial ten-μm-thick sections. Extracted DNA was amplified by nested PCR. Mutations of PTEN and p53 were examined by bidirectional DNA sequencing. Results: It was acknowledged by experiments that the PTEN and p53 mutation frequency in EAOCs were significantly higher than that in aEMs and EMs. There was significant difference to compare EAOCs with EMs (p < 0.01, p < 0.05), and converse to compare with aEMs (p > 0.05), respectively. No definite involvement between the frequency of PTEN and p53 mutations in EAOCs and age difference, histological type, clinical stage, pathological grade, and whether accompanied by metastasis (p > 0.05); however, a decreasing trend of PTEN mutation with the increased age, decreased clinical stage and pathological grade, and when accompanied by metastasis was detected. Adversely, an increasing trend of p53 mutation was represented. In EAOCs group, the authors detected eight PTEN and four p53 mutation events, respectively. Moreover, one case occurred PTEN and p53 mutation simultaneously. With 23 EAOCs, two cases which fulfilled the histological criteria in malignant transformation of endometriosis, which may be a specific entity distinct from non-endometriosis-associated ovarian cancer, the authors named them the OCEMs, occurred PTEN or p53 mutation, respectively. Conclusion: The present study suggested that the mutation and functional incapacitation of certain tumor-related genes may be involved in malignant transformation of endometriosis. PTEN mutation is the pristine event, but p53 mutation is the late.

Keywords

Endometriosis; Endometriosis-associated ovarian cancer; Ovarian cancer arising from endometriosis; Atypical hyperplasia; PTEN Gene; p53 Gene; Mutation; Nested PCR; Bidirectional DNA sequencing.

Cite and Share

X. Ma,Y. Hui,L. Lin,Y. Wu,X. Zhang,X. Qin. Possible relevance of tumor-related genes mutation to malignant transformation of endometriosis. European Journal of Gynaecological Oncology. 2016. 37(1);89-94.

References

[1] Eskenazi B., Warner M.L.: “Epidemiology of endometriosis”. Obstet. Gynecol. Clin. North. Am., 1997, 24, 235.

[2] Olive D.L.: “Medical therapy of endometriosis”. Semin. Reprod. Med., 2003, 21, 209.

[3] Brinton L.A., Gridley G., Persson I., Baron J., Bergqvist A.: “Cancer risk after a hospital discharge diagnosis of endometriosis”. Am. J. Obstet. Gynecol., 1997, 176, 572.

[4] Kobayashi H., Sumimoto K., Moniwa N., Imai M., Takakura K., Kuromaki T., et al.: “Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan”. Int. J. Gy-necol. Cancer, 2007, 17, 37.

[5] Aris A.: “Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada”. J. Ovarian Res., 2010, 3, 2.

[6] Melin A., Sparén P., Persson I., Bergqvist A.: “Endometriosis and the risk of cancer with special emphasis on ovarian cancer”. Hum. Reprod., 2006, 21, 1237.

[7] Seidman J.D.: “Prognostic importance of hyperplasia and atypia in endometriosis”. Int. J. Gynecol. Pathol., 1996, 15, 1.

[8] Stern R.C., Dash R., Bentley R.C., Snyder M.J., Haney A.F., Robboy S.J.: “Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types”. Int. J. Gynecol. Pathol., 2001, 20, 133.

[9] Erzen M., Kovacic J.: “Relationship between endometriosis and ovarian cancer”. Eur. J. Gynaec. Oncol., 1998, 19, 553.

[10] Fukunaga M., Nomura K., Ishikawa E., Ushigome S.: “Ovarian atypical endometriosis: its close association with malignant epithelial tumours”. Histopathology, 1997, 30, 249.

[11] Modesitt S.C., Tortolero-Luna G., Robinson J.B., Gershenson D.M., Wolf J.K.: “Ovarian and extraovarian endometriosis-associated cancer”. Obstet. Gynecol., 2002, 100, 788.

[12] Viganó P., Somigliana E., Chiodo I., Abbiati A., Vercellini P.: “Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis”. Hum. Reprod. Update, 2006, 12, 77.

[13] Nishida M., Watanabe K., Sato N., Ichikawa Y.: “Malignant transformation of ovarian endometriosis”. Gynecol. Obstet. Invest., 2000, 50, 18.

[14] Sampson J.A.: “Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ”. Arch. Surg., 1925, 10, 1.

[15] Scott R.B.: “Malignant changes in endometriosis”. Obstet. Gynecol., 1953, 2, 283.

[16] Frank T.S., Svoboda-Newman S.M., His E.D.: “Comparison of methods for extracting DNA from formalin-fixed paraffin sections for nonisotopic PCR”. Diagn. Mol. Pathol., 1996, 5, 220.

[17] Sigal A., Rotter V.: “Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome”. Cancer Res., 2000, 60, 6788.

[18] Lasky T., Silbergeld E.: “P53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers”. Environ. Health Perspect., 1996, 104, 1324.

[19] Akbari M., Hansen M.D., Halgunset J., Skorpen F., Krokan H.E.: “Low copy number DNA template can render polymerase chain reaction error prone in a sequencedependent manner”. J. Mol. Diagn., 2005, 7, 36.

[20] Ness R.B.: “Endometriosis and ovarian cancer: thoughts on shared pathophysiology”. Am. J. Obstet. Gynecol., 2003, 189, 280.

[21] Nakako S., Hajime T., Masato N.: “Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary”. Cancer Res., 2000, 60, 7052.

[22] Jiang X., Morland S.J., Hitchcock A., Thomas E.J., Campbell I.G.: “Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage”. Cancer Res., 1998, 58, 1707.

[23] Dinulescu D.M., Ince T.A., Quade B.J., Shafer S.A., Crowley D., Jacks T.: “Role of Kras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer”. Nat. Med., 2005, 11, 63.

[24] Xu B., Hamada S, Kusuki I, Itoh R, Kitawaki J.: “Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis”. Gynecol. Oncol., 2011, 120, 239. doi: 10.1016/ j.ygyno.2010.10.036. Epub 2010 Dec 3.

[25] Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., Noguchi M.: “Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary”. Cancer Res., 2000, 60, 7052.

[26] Nakayama K., Toki T., Zhai Y.L., Lu X., Horiuchi A., Nikaido T., Konishi I. Fujii S.: “Demonstration of focal p53 expression without genetic alterations in endometriotic lesions”. Int. J. Gynecol. Pathol., 2011, 20, 227.

[27] Prefumo F., Venturini P.L., Fulcheri E.: “Analysis of p53 and cerbB- 2 expression in ovarian endometrioid carcinomas arising in endometriosis”. Int. J. Gynecol. Pathol., 2003, 22, 83.

[28] Saintz de la Cuesta R., Izquierdo M., Canamero M., Granizo J.J., Manzarbeitia F.: “Increased prevalence of p53 overexpression from typical endometriosis to atypical endometriosis and ovarian cancer associated with endometriosis”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2004, 113, 87.

[29] Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al.: “Crucial role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis”. Nature, 2005, 436, 725.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top